Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Reuters NewMedia - December 29, 2003
Gen-Probe said the FDA approved running its Aptima Combo assay, an already approved nucleic acid test for simultaneous testing for Chlamydia trachomatis and Neisseria gonorrhea, on the company's Tigris DTS System.
The Tigris System is fully automated and is expected to allow laboratories to cut labor costs, minimize errors, and increase productivity, Gen-Probe said.
The company said it plans to expand its group of clinical diagnostic and blood screening tests that can be performed on the Tigris system.
Earlier this month, Gen-Probe filed an amended Investigational New Drug application with the FDA to initiate clinical trials of the Procleix Ultrio assay, which will test for HIV-1, hepatitis C and hepatitis B in blood, plasma, organs and tissue, on the Tigris System, the company said.
Gen-Probe said it intends to begin clinical trials of the assay on the Tigris System in January.
Gen-Probe shares traded up $3.68 at $36.85 on the Nasdaq, after hitting a record high of $37.23 earlier.
031229
RE031230
Copyright © 2003 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .